Philips Reports Strong Q2 2026 Growth and AI Innovation
Amsterdam, Netherlands, July 27, 2026 Royal Philips has reported solid second-quarter 2026 financial results, driven by 4% comparable sales...
oral therapy
Advertisement
InnoCare Phase III TYK2 Study Meets Psoriasis Endpoint
Beijing, July 27, 2026 InnoCare Pharma has announced that its novel TYK2 (Tyrosine Kinase 2) inhibitor fadeucravacitinib (ICP-488) successfully...
Nuvectis Pharma Announces China Approval of Ciprocopan for PNH
FORT LEE, N.J., July 23, 2026 Nuvectis Pharma, Inc. announced that ciprocopan (NXP100) has received marketing approval from China’s...
Apnimed Targets First Oral Sleep Apnea Therapy with FDA NDA
CAMBRIDGE, Mass., July 14, 2026 Apnimed, Inc. has achieved a significant regulatory milestone after the U.S. Food and Drug...
Lynk Pharmaceuticals Completes Phase III AS Trial Enrollment
HANGZHOU, China, SHANGHAI & BOSTON — July 14, 2026 Lynk Pharmaceuticals Co., Ltd. has announced the successful completion of...
Advertisements
NextCure and Avere Strengthen Oral IL-23 Development
SAN FRANCISCO, July 14, 2026 NextCure and privately held Avere Therapeutics have entered into a definitive all-stock merger agreement...
Aligos Completes Phase 2 B-SUPREME Enrollment
SOUTH SAN FRANCISCO, Calif., July 13, 2026 Aligos Therapeutics announced the completion of patient enrollment in both parts of...
Vandria Reports Positive Phase 1 VNA-318 Data
LAUSANNE, Switzerland, July 13, 2026 Vandria announced new Phase 1 clinical data demonstrating that its investigational small molecule VNA-318...
Pharvaris Advances Oral HAE Therapy with FDA NDA Acceptance
ZUG, Switzerland, July 6, 2026 Pharvaris announced that the U.S. Food and Drug Administration (FDA) has accepted the New...
Can-Fite Completes Phase 3 Psoriasis Trial Enrollment
RAMAT GAN, Israel, July 6, 2026 Can-Fite BioPharma announced the completion of enrollment of the first 247 patients in...
Advertisement
